You just read:

Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

News provided by

Daiichi Sankyo Company, Limited

18 Oct, 2018, 13:00 BST